Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2009. The report discloses a material change in GSK's equity interest in OctoPlus N.V., a Netherlands-based pharmaceutical product and drug delivery company.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction.
Material Changes
- Increased Stake: On February 25, 2009, S.R. One, Limited (a wholly owned US subsidiary of GSK) increased its interest in OctoPlus N.V. to 16.9%.
- Share Count: GSK's total holding now comprises 5,096,846 ordinary shares of OctoPlus.
- Transaction Mechanism: The increase was achieved through the conversion of an existing convertible loan between S.R. One and OctoPlus into ordinary shares.
- Regulatory Trigger: The additional 3,115,012 shares pushed the holding above the 15% disclosable threshold under the rules of the Netherlands Authority for the Financial Markets (AFM).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the regulatory requirement to disclose the shareholding increase.
Investor Verification Checklist
- Verify the current trading price and market capitalization of OctoPlus N.V. on Euronext Amsterdam.
- Confirm the terms of the converted convertible loan and any remaining debt obligations between GSK and OctoPlus.
- Review the AFM announcement dated February 26, 2009, for any additional regulatory details regarding the 16.9% stake.
- Assess the strategic rationale for increasing the stake in OctoPlus given the broader pharmaceutical market conditions in early 2009.